• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

From MGUS to Myeloma: Understanding and Interrupting Disease Progression

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles The 2025 ASCO Annual Meeting discusses the latest advancements in understanding and treating precursor diseases. Read More

Darolutamide Approved by FDA for Metastatic Castration-Sensitive Prostate Cancer

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles The FDA has approved darolutamide for patients with metastatic castration-sensitive prostate cancer after positive results in the ARANOTE clinical trial. Read More

June-July 2025: Upcoming NCPA Items for Pharmacy Teams

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

FDA Approves Nubeqa in Metastatic Castration-Sensitive Prostate Cancer

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data. Read More

COCOON Dermatologic Regimen Improves QOL in EGFR+ Lung Cancer

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles COCOON dermatologic management lessened skin side effects and improved quality of life versus standard care for patients with lung cancer. Read More
« Older Entries
Next Entries »

Recent Content

  • Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
  • A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
  • Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
  • Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
  • Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Incidence and prevalence of clinically detected smoldering multiple myeloma within the general population: a retrospective observational cohort study
  • The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma
  • What Does Multiple Myeloma Mean?
  • FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT